钬激光前列腺剜除术与机器人辅助单纯前列腺切除术治疗良性前列腺增生的比较分析:系统综述与Meta分析
该系统综述与Meta分析比较钬激光前列腺剜除术(HoLEP)与机器人辅助单纯前列腺切除术(RASP)治疗良性前列腺增生(BPH)的疗效、效率与安全性。结果显示两者功能结局相似,但HoLEP在手术时间、住院时间、导尿时间及输血风险上更优,RASP的2级及3级及以上并发症风险更高。
要点
- HoLEP与RASP治疗BPH的功能结局(最大尿流率、残余尿量)相似。
- HoLEP较RASP缩短手术时间49.48分钟、住院时间1.5天、导尿时间3.8天。
- HoLEP显著降低输血风险75%;RASP的2级并发症风险为1.87倍,3级及以上为3.41倍。
核心结论
- HoLEP与RASP均能有效治疗BPH;HoLEP在恢复指标和输血率上占优,RASP便于在具备机器人设备的机构开展。
研究设计与样本
- 遵循PRISMA指南的系统综述与Meta分析,方案注册于Prospero(CRD42024509627)。
- 检索Medline、Embase、Web of Science、Scopus和CINAHL至2024年2月1日,纳入比较HoLEP与RASP治疗BPH患者的研究。
- 采用Newcastle Ottawa量表评估偏倚风险。
主要发现
- HoLEP与RASP在最大尿流率和残余尿量等功能结局上相似。
- HoLEP较RASP减少手术时间49.48分钟、住院时间1.5天、导尿时间3.8天。
- HoLEP显著降低输血风险75%。
- RASP患者发生2级并发症的风险为1.87倍,发生3级及以上并发症的风险为3.41倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: As the prevalence of benign prostatic hyperplasia (BPH) increases, the demand for surgical interventions that optimize patient outcomes while minimizing complications grows. This systematic review compares the efficacy, efficiency, and safety of holmium laser enucleation of the prostate (HoLEP) with robotic-assisted simple prostatectomy (RASP), providing insights for evidence-based surgical decision-making in BPH treatment. MATERIALS AND METHODS: Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, the study protocol was registered with Prospero (CRD42024509627). Searches were conducted in Medline, Embase, Web of Science, Scopus, and Cumulative Index to Nursing and Allied Health Literature up to February 1, 2024, to include studies that compare HoLEP and RASP in patients with BPH. Risk of bias was evaluated using the Newcastle Ottawa Scale. RESULTS: HoLEP and RASP demonstrated equivalent effectiveness in treating BPH, as shown by similar functional outcomes such as maximum urinary flow rate and postvoid residual volume. However, HoLEP outperformed RASP in several operational efficiency metrics, reducing operative time by 49.48 minutes, hospitalization duration by 1.5 days, and catheterization period by 3.8 days. HoLEP also significantly reduced the risk of blood transfusions by 75%. Patients undergoing RASP were 1.87 times more at risk for grade 2 complications and 3.41 times more at risk for developing grade 3 or above complications. CONCLUSIONS: HoLEP and RASP are effective for managing BPH. HoLEP shows advantages in recovery metrics and lower blood transfusion rates, while RASP benefits from ease of implementation in robotic-equipped facilities. Optimizing surgical outcomes will depend on reducing disparities in technique adoption, improving surgical training, and aligning with evidence-based guidelines.
引用
- Benzouak T, Addar A, Prudencio-Brunello MA, et al. Comparative Analysis of Holmium Laser Enucleation of the Prostate and Robotic-Assisted Simple Prostatectomy in Benign Prostatic Hyperplasia Management: A Systematic Review and Meta-Analysis. J Urol. 2024. PMID: 39423101. doi:10.1097/JU.0000000000004297
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。